GPHL presents its work plan for 2H20

2020-07-31 16:30:55 GPHL GPHL

On July 28th, GPHL's 1H20 results meeting was held at the Baiyunshan Pharmaceutical General Factory (BPGF). At the meeting, GPHL's chairman Li Chuyuan delivered a summary speech and General Manager Yang Jun summarized the Group's work in 1H20 and presented a report on the work plan for 2H20.

On July 28th, GPHL's 1H20 results meeting was held at the Baiyunshan Pharmaceutical General Factory (BPGF)

For battling COVID-19, GPHL played an active role in guaranteeing the reserve of medicines, medical equipment and supplies for Guangdong province and kept the promises of “no price hike, no production stoppage, quality assurance, and public good first”.

Since the Spring Festival of 2020, over 5,000 staff members have been working on the frontline. They worked overtime to produce antiviral drugs and resumed the production of Chloroquine Phosphate Tablets as early as possible.

So far GPHL has secured an inventory of over 100 million protective items and run Suikang microprogram smoothly to provide more than 270 million masks, benefiting more than 14 million consumers.

For poverty alleviation, GPHL issued 200 million RMB worth of Ciningji vouchers, invited Dr. Zhong Nanshan to promote this soft drink in a live broadcast and launched a marketing campaign across the Group.

In Meizhou, a city in South China, GPHL took targeted measures to lift local people out of poverty and helped them access necessary education. All 358 rural residents in 141 households living below the current poverty line have been raised out of poverty.

GPHL General Manager Yang Jun summarizes the Group's work in 1H20 and presented a report on the work plan for 2H20.

For manufacturing and operation, GPHL expanded its presence in the market of COVID-19 related products, tried to promote traditional Chinese medicine (TCM) in a trendy and modern manner, developed retail and e-commerce business and established Baiyunshan Yihu Health and Technology for producing masks and protective clothing used by medical workers.

In the first half of 2020, a BPGF project was included in the major projects of the Ministry of Science and Technology and a project conducted by GPHL’s subsidiary Guangzhou Hanfang Pharmaceutical placed second in the Science and Technology Progress Award of Guangdong Province. The Group built two more provincial engineering centres, namely the Guangdong Province Engineering Research Centre for Medicines in Andrology and Guangdong Province Engineering Research Centre for Herbal Drinks.

In addition, Guangzhou Pharmaceutical Group (Macau) International Development Co. was established in Macao. GPHL’s subsidiary, Guangzhou Pharmaceuticals Corporation, completed its shareholding system reform. Guangzhou government awarded the ‘2020 major project status’ to five GPHL projects, such as the R&D and marketing headquarters located at the Guangzhou's International Biotech Island (GIBI), the logistics centre (Phase I) of GPHL Biomedical City in Baiyun District of Guangzhou as well as Wanglaoji’s Nansha Base (Phase I).

GPHL has received a variety of awards in 1H20. For example, it topped China's top 100 TCM companies for the ninth consecutive year. Baiyunshan ranked second in the product brand section of the 2020 China’s Brand Value List. GPHL's Shennong Caotang Museum was listed as a key national cultural export project in the year 2019-2020, which was also the only TCM culture project from Guangdong.

GPHL chairman Li Chuyuan delivers a summary speech.

In conclusion, GPHL chairman Li Chuyuan pointed out that GPHL should:

1. Revive its legacy TCM brands on a case by case basis by utilizing those brands’ specialities and strengths.

2. Promote system and mechanism innovation and expedite the Group’s overall reform.

3. Explore new landscapes of possibility for industrial development by speeding up the construction of the logistics centre (Phase I) of GPHL Biomedical City in Baiyun District of Guangzhou, the R&D and marketing headquarters located at the GIBI, Wanglaoji’s Nansha Base (Phase I) and Tonghe Healthcare and Rehabilitation Centre.

4. Support Guangzhou Pharmaceutical Group (Macau) International Development Co. and facilitate collaboration in the TCM industry among Guangdong, Hong Kong and Macao.

5. Fulfil social responsibility for poverty alleviation and generate revenue by completing Ciningji's 500-million-RMB project and developing the roxburgh rose industry.

6. Explore new approaches for resource integration, further integrate internal marketing and increase resource efficiency.

7. Boost high-quality development of the Group and enhance efficiency and quality in the workplace.

Authors: Monica & Michelle

Editors: Olivia & Jerry

NULL